International Aids Society ((new))

In the four decades since the emergence of the HIV epidemic, the world has transformed a once-lethal diagnosis into a manageable chronic condition for millions. Central to this transformation is the International AIDS Society (IAS). Founded in 1988, the IAS stands as the world’s largest association of HIV professionals, serving as a critical bridge between scientific discovery, policy implementation, and community activism. Through its convening power and unwavering commitment to evidence-based solutions, the IAS has been instrumental in shaping the global response to one of the most complex health challenges in modern history.

Advocacy and Human Rights: The society recognizes that science alone cannot end the epidemic. They actively campaign against the criminalization of HIV, the stigma surrounding the virus, and the systemic barriers that prevent marginalized populations from accessing life-saving care. Major Global Events: The IAS Conferences international aids society

The International AIDS Society (IAS) stands as the world’s largest association of HIV professionals, serving as a prestigious bridge between clinical science, global policy, and grassroots activism. Founded in 1988, the organization has spent decades orchestrating the global response to the HIV/AIDS epidemic. With members in more than 170 countries, the IAS is the definitive voice for scientists, healthcare providers, and advocates dedicated to ending HIV as a threat to public health. The Evolution of the IAS In the four decades since the emergence of

: Championing evidence-based policies and promoting independent research. Through its convening power and unwavering commitment to

Scientific Excellence: The IAS is the primary convener of the world’s most significant HIV conferences. These events serve as the "town square" for the latest breakthroughs in antiretroviral therapy (ART), vaccine research, and cure strategies.

The IAS’s greatest intellectual legacy is the concept of .

The fight isn't over. We still lack a vaccine. Stigma is rebranding itself. Funding is flatlining.